Nektar Therapeutics (NKTR) Posts Q2 EPS Loss of $0.32, Revenues 60% Y/Y
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $59.38 +2.98%
Revenue Growth %: -11.4%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: -11.4%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.32), $0.01 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $14.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
- Scholastic Corp (SCHL) Misses Q1 EPS by 23c
- Cintas beats estimates but stock edges lower
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
